INTRODUCTION
============

Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is common since both infections share similar routes of transmission. Patients with HCV and HIV coinfection have a more rapid rate of progression to cirrhosis than HCV monoinfected patients \[[@b1-kjim-2015-353]\]. As death rates from opportunistic infections declined and the life expectancy is extended in the era of potent antiviral therapy in HIV infected patients, chronic hepatitis C has becomes a major cause of mortality in HIV-infected patients \[[@b2-kjim-2015-353]\]. Marked advancements have recently been made in the antiviral treatment of HCV infection. Successful treatment of HCV infection has been shown to stop fibrosis progression, prevent liver-associated diseases and mortality in HIV-infected patients \[[@b3-kjim-2015-353]\]. Therefore, guidelines recommend screening of all HIV-infected patients for HCV infection \[[@b4-kjim-2015-353]\]. These recommendations also apply to patients with normal aminotransferases, since patients can have advanced fibrosis despite these laboratory findings \[[@b5-kjim-2015-353]\]. On the other hand, because sexual transmission of HCV is not significantly frequent, routine follow-up of HCV tests in HIV-infected patients have not been recommended so far unless the patients had risk factors of HCV infection \[[@b6-kjim-2015-353]-[@b10-kjim-2015-353]\].

However, recent studies conducted in the United States, Europe, and Australia showed that incidence of HCV infection increased and the main transmission route of HCV infection was sexual contact among HIV-infected men who have sex with men (MSM) \[[@b11-kjim-2015-353]-[@b14-kjim-2015-353]\]. Increasing incidence of HCV in HIV-infected patients, combined with recent advances in antiviral therapy of HCV infection augmented the necessity of HCV screening. Therefore, the European AIDS clinical society recommended HCV testing for all of the HIV infection at time of diagnosis and thereafter annual follow-up \[[@b15-kjim-2015-353]\]. In Japan and Taiwan, which are resource-rich and low HCV prevalent countries in Asia, increasing HCV incidence among HIV infected patients was recently reported \[[@b16-kjim-2015-353],[@b17-kjim-2015-353]\]. Those studies also suggested routine follow-up HCV screening for HIV-infected patients. However, routine follow-up screening may not be cost effective even in a resource-rich setting if incidence of HCV in HIV-infected patients is very low. In that case, targeted screening within the high risk group could be more effective.

However, little is known about HCV epidemiology among HIV infected patients in South Korea. Therefore we designed this study to examine the incidence of HCV infection and risk factors of HCV infection among HIV infected persons in South Korea.

METHODS
=======

Study design and patients
-------------------------

A retrospective cohort study was conducted from January 2000 to December 2014 at a tertiary care hospital in Pusan, South Korea. All HIV-infected patients who visited Pusan National University Hospital were identified from computerized records. To examine the prevalence and risk factors of HCV infection in HIV infected patients, patients with ≥ 1 anti-HCV antibody tests (HCV Ab) before December 2013 were enrolled in this study. To examine the incidence of HCV in HIV infected patients, subgroup analyses were performed with the patients with a negative baseline HCV Ab who had subsequent anti-HCV Ab more than 6 months apart. Demographics and clinical data were collected from a retrospective review of medical records. The Institutional Review Board of Pusan National University Hospital approved the study protocol and informed consent was waived.

Laboratory tests and definitions
--------------------------------

HCV Ab, CD4 cell count, HIV-1 viral load, and rapid plasma reagin (RPR) test are routinely performed on the initial visit to our institute. Patients with positive HCV Ab subsequently undergo HCV-RNA measurement and genotyping test. Repeat HCV Ab tests were performed according to the decision of the treating physician.

Prevalent HCV was defined as positive for HCV Ab at the baseline or during observation. Incident HCV was defined as positive-conversion of HCV Ab during follow-up. Clinical categories were defined by the 1993 Centers for Disease Control and Prevention classification criteria \[[@b18-kjim-2015-353]\]. Incident syphilis, a marker of active high risk sexual behavior, was defined as a positive-conversion of RPR test or ≥ 4-fold increase of quantitative RPR titer.

Statistical analysis
--------------------

SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. For comparison of baseline characteristics between HCV Ab positive and negative group, Pearson chi-square test was used for categorical variables, and the Student *t* test for continuous variables. Multivariate logistic regression analysis was used for evaluation of the risk factors of HCV infection in HIV infected patients. Poisson regression was used for comparison of incidence rates according to periods and HIV transmission route. Tests of significance were 2-tailed, *p* \< 0.05 was considered significant.

RESULTS
=======

Demographics
------------

Between January 2000 and December 2013, 996 HIV-infected patients visited our hospital. Of these, 206 patients (20.7%) who had no baseline HCV Ab tests were excluded. Mean age of 790 patients (79%) with baseline HCV Ab tests was 44.0 ± 11.9 years and 690 patients (87.3%) were male including 320 (40.5%) MSM ([Fig. 1](#f1-kjim-2015-353){ref-type="fig"}).

Prevalence of HCV in HIV infected patients
------------------------------------------

Of 790 HIV-infected patients, 45 patients (5.7%) were positive for HCV Ab and 745 patients (94.3%) were negative. In bivariable analysis, injecting drug use (IDU), non-sexually infected HIV, female sex, and HIV RNA \> 100,000 copies/mL showed significant association with prevalent HCV infection ([Table 1](#t1-kjim-2015-353){ref-type="table"}). In multivariable analysis intravenous (IV) drug use (adjusted odds ratio, 16.20; 95% confidence interval \[CI\], 1.56 to 167.89; *p* \< 0.01) was the only independent risk factor for HCV co-infection in HIV patients.

Incidence of HCV in HIV infected patients
-----------------------------------------

A total of 384 patients who had subsequent HCV Ab tests more than 6 months from the initial test were included for incidence analysis. Conversion to HCV Ab positivity was observed in four of 384 included patients, with an incidence rate of 2.22 (95% CI, 0.60 to 5.80)/1,000 person-years (PYs); 164.89 (95% CI, 34.00 to 481.88)/1,000 PYs in patients with IDU, 1.40 (95% CI, 0.35 to 7.79)/1,000 PYs in MSM who denied IDU, and 0 (95% CI, 0 to 3.67)/1,000 PYs in man who had sex with women (MSW) who denied IDU. Among four incident HCV patients, three were MSM and three had history of IV drug use, including two MSM and one MSW. All of the incident HCV infections developed within recent 5 years. However, there was no significant increase in incidence rate of HCV in HIV-infected MSM (*p* = 0.243) and total patients in 2010 to 2014 versus 2000 to 2009 (*p* = 0.119) ([Table 2](#t2-kjim-2015-353){ref-type="table"}). During the study period, activity of high risk sexual behavior among enrolled patients was estimated to be constant since there was no significant change in the incidence of syphilis ([Table 3](#t3-kjim-2015-353){ref-type="table"}).

HCV genotype distribution
-------------------------

Among the 45 HCV Ab positive patients, 21 patients were positive for HCV RNA. HCV genotype analysis was performed in 19 patients and the patients were divided into genotype 1 (n = 13, 68.4%) and 2 (n = 6, 31.6%). All of the subtype of genotype 1 was 1b. The subtypes of genotype 2 were 2 (n = 1, 5.3%), 2a/2c (n = 4, 21.1%), and mixed 2 & 2a/2c (n = 1, 5.3%). Genotype 1b infection was more prevalent in unmarried patients (1b 90% vs. non-1b 10%) and IDU (1b 6/7, 87.5% vs. non-1b 12.5%) although there was no statistical significance.

DISCUSSION
==========

There was no significant increase of HCV incidence in South Korea. Only four HIV-infected patients were newly infected with HCV during the study period (1,551 PYs) at our hospital, with an incidence of 2.22/1,000 PYs. The incidence of 2.22/1,000 PYs was lower than that reported in North America and Western Europe and was also lower than that of resource-rich countries in Asia such as Japan and Taiwan \[[@b14-kjim-2015-353],[@b16-kjim-2015-353],[@b17-kjim-2015-353],[@b19-kjim-2015-353],[@b20-kjim-2015-353]\]. Despite a recent minimal increase in HCV incidence in HIV-infected patients, there was no statistically significant increase over the observation periods. In addition, HCV incidence of MSM also was not significantly increased and most incident HCV patients were identified as IV drug users. Incidence of syphilis was used as a marker of ongoing sexual activity and consistent incidence of syphilis suggests that sexual activity of included patients was consistent during study periods. Although the reason for the discrepancy of HCV incidence in HIV infected patients between Korea and other resource-rich Asian countries was not clear, our data highlighted the importance of local epidemiologic data because data from other countries cannot be easily applied even though the country is geographically, racially close.

European guidelines recommended annual follow-up HCV Ab tests \[[@b15-kjim-2015-353]\]. One recent study conducted in Japan suggested that routine rescreening for HCV is necessary among HIV-infected MSM in resource-rich settings in Asia \[[@b16-kjim-2015-353]\]. A cost-effectiveness study which assumed a societal willingness to pay \$100,000 per quality-adjusted life-year gained suggested that screening with 6-month liver function tests and a 12-month HCV Ab test was the optimal strategy when the HCV infection incidence was ≤ 12.5 cases/1,000 PYs \[[@b21-kjim-2015-353]\]. In our study, incidence of HCV in HIV infected patients was 2.22 PYs. Therefore annual rescreening for HCV Ab test is efficient in Korea if Korean society is willing to pay \$100,000 per quality-adjusted life-year gain of HIV infected patients \[[@b21-kjim-2015-353]\].

Our study was the first epidemiologic study on HCV infections among HIV-infected patients in South Korea. HCV prevalence among HIV-infected patients was 5.2%, higher than in the general population (0.78%) in Korea \[[@b22-kjim-2015-353]\]. The distribution of genotype 1 and 2 was almost equal in HCV infected patients without HIV infection in Korea \[[@b22-kjim-2015-353],[@b23-kjim-2015-353]\]. However, approximately 70% of Korean HIV/HCV co-infected patients and 87.5% of HIV/HCV co-infected patients with IDU had genotype 1b HCV. Sustained virologic response (SVR) rate of pegylated interferon α plus ribavirin in non-HIV infected patients of 40% to 50% has been reported for genotype 1 and 70% to 80% for genotype 2 and 3 \[[@b24-kjim-2015-353],[@b25-kjim-2015-353]\]. The benefit of antiviral therapy against HCV in HIV infected patients has been debated because of considerably low cure rates of genotype 1 HCV infection in HIV infected patients \[[@b26-kjim-2015-353]\]. However, SVR rates of genotype 1b HCV infected patients was higher in Korea than in Western countries, which might be due to the high prevalence of IL28B-CC type among Koreans \[[@b27-kjim-2015-353]-[@b29-kjim-2015-353]\]. Furthermore, on the basis of a major breakthrough in the treatment of chronic hepatitis C using directly acting antivirals, such as telaprevir or boceprevir combined with pegylated interferon α and ribavirin, we have entered a new era of hepatitis C therapeutics with a much higher probability of curing HCV infection including genotype 1b in HIV infected patients \[[@b30-kjim-2015-353],[@b31-kjim-2015-353]\]. Recent studies demonstrated that use of interferon-free regimens such as sofosbuvir/ribavirin, daclatasvir/asunaprevir, and sofosbuvir/daclatasvir is comparable with interferon containing regimens in 1b HCV infected patients \[[@b32-kjim-2015-353]\]. A better understanding of HCV epidemiology in HIV infected patients could be helpful to medical communities and government agencies in development of effective strategies for treatment of HCV.

Prevalence of HIV infected patients in South Korea is very low. In 2014, in a population of 50,220,000, there were 9,615 cumulative HIV-infected patients \[[@b33-kjim-2015-353]\]. Approximately 14.1% of Korean HIV infected patients were notified from Busan and Gyeongsangnam-do, the Southeastern part of Korea \[[@b34-kjim-2015-353]\]. Therefore our study included approximately 75% of HIV-infected patients in the Southeastern part of Korea and might provide useful information to understanding HIV/HCV coinfection in South Korea.

In our study, in multivariable analysis, the only risk factor for HCV infection among HIV-infected patients was experience of IV drug use.

Our study has several limitations that need to be acknowledged. First, this study was a retrospective observational study and HCV Ab were tested in clinical practice. We cannot rule out the presence of unmeasured confounding and prevent under reporting of IV drug use history. It is also possible that our data were overestimated because 41.8% of the patients with negative baseline HCV Ab test underwent follow-up HCV Ab tests and clinically suspicious patients tended to undergo follow-up HCV Ab tests. Second, our study was conducted at a single center in the southeastern region of Korea. Therefore our findings may not be generalized to other regions of the country. However, Busan could be an appropriate location for study of HCV incidence in HIV infected patients because Busan is one of the most prevalent cities for HCV infections in general populations of Korea \[[@b22-kjim-2015-353]\].

In conclusion, this study showed that experience of IV drug use was an independent risk factor for HCV infection in HIV patients in Korea. Prevalence of HCV infection was low and incidence of HCV infection was not significantly increased in HIV-infected patients in South Korea. Further study is warranted for appropriate recommendation for routine annual follow-up of HCV Ab test in HIV-infected patients.

KEY MESSAGE
===========

1\. Prevalence of hepatitis C virus (HCV) in human immunodeficiency virus (HIV)-infected patients was 5.2%.

2\. Intravenous drug use was independent risk factor of prevalent HCV infection in HIV-infected patients.

3\. HCV incidence was 2.2/1,000 person-years and there was no significant increase of HCV incidence.
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###### 

Comparison of characteristics between positive and negative anti-HCV Ab tests in HIV infected patients

  Characteristic                               Total (n = 790)     Positive HCV Ab (n = 45)   Negative HCV Ab (n = 745)   *p* value
  -------------------------------------------- ------------------- -------------------------- --------------------------- -----------
  Age, yr                                      44.0 ± 11.9         46.2 ± 10.2                43.2 ± 12.0                 0.23
   \< 30                                       112 (14.2)          5 (11.1)                   107 (14.4)                  0.20
   \> 60                                       71 (9.0)            4 (8.9)                    67 (9.0)                    \> 0.99
  Male sex                                     690 (87.3)          35 (77.8)                  655 (87.9)                  0.05
  Married                                      305 (38.9)          16 (35.6)                  289 (39.1)                  0.64
  HIV duration, yr                             0.36 (0.04--4.61)   0.22 (0.01--3.66)          0.36 (0.04--4.81)           0.15
  Self reported risk factor of HIV infection                                                                              
   Heterosexual                                456 (57.7)          22 (48.9)                  434 (58.3)                  0.22
   MSM                                         320 (40.5)          13 (28.9)                  307 (41.2)                  0.10
   Non-sexual infection                        17 (2.2)            12 (26.7)                  5 (0.7)                     \< 0.01
  Syphilis (VDRL at baseline)                  227 (30.5)          13 (31.0)                  214 (30.4)                  0.94
  History of IDU                               14 (1.8)            11 (24.4)                  3 (0.4)                     \< 0.01
  CD4+ cell count, cells/mm^3^                 252.9 ± 236.2       230.7 ± 191.8              254.1 ± 238.4               0.54
   \< 200                                      382 (48.4)          19 (43.2)                  363 (49.3)                  0.43
   \> 500                                      114 (14.6)          5 (11.4)                   109 (14.8)                  0.53
  HIV RNA at initial visit, copies/mL                                                                                     
   \< 10,000                                   170 (23.0)          7 (15.9)                   163 (23.5)                  0.25
   10,000--100,000                             191 (25.8)          7 (15.9)                   184 (26.5)                  0.12
   \> 100,000                                  378 (51.2)          30 (68.2)                  348 (50.1)                  0.02
  CDC categories                                                                                                          
   A                                           482 (61)            28 (62.2)                  454 (60.9)                  0.86
   B                                           71 (9.0)            5 (11.1)                   66 (8.9)                    0.61
   C                                           237 (30)            12 (26.7)                  225 (30.2)                  0.62

Values are presented as mean ± SD, number (%), or median (interquartile range).

HCV, hepatitis C virus; Ab, antibody; HIV, human immunodeficiency virus; MSM, men who have sex with men; VDRL, Venereal Disease Research Laboratory test; IDU, injecting drug use; CDC, Centers for Disease Control and Prevention.

###### 

Incidence of hepatitis C virus infection (cases/1,000 person-years) in human immunodeficiency virus patients (95% confidence interval)

  Variable                                             Number   Overall period           2000--2009      2010--2014
  ---------------------------------------------------- -------- ------------------------ --------------- ------------------------
  Total                                                4/384    2.22 (0.60--5.68)        0 (0--4.04)     3.78 (1.03--9.67)
  Women                                                0/52     0 (0--11.96)             0 (0--28.17)    0 (0--20.77)
  Men total                                            4/332    2.58 (0.70--6.60)        0 (0--4.71)     4.37 (1.19--11.20)
   MSM                                                 3/165    4.13 (0.85--12.08)       0 (0--11.01)    6.62 (1.36--19.34)
   MSM no drug                                         1/162    1.40 (0.35--7.79)        0 (0--11.23)    2.23 (0.57--12.44)
   MSW                                                 1/167    1.22 (0.03--6.81)        0 (0--8.31)     2.18 (0.06--12.20)
   MSW no drug                                         0/166    0 (0--3.67)              0 (0--8.31)     0 (0--6.57)
  IDU^[a](#tfn1-kjim-2015-353){ref-type="table-fn"}^   3/4      164.89 (34.00--481.88)   0 (0--367.11)   299.25 (61.71--874.54)

MSM, men who have sex with men; MSW, men who sex with women; IDU, injecting drug use.

Three MSM and one MSW was included in the denominator.

###### 

Incidence of syphilis (cases/1,000 person years) in human immunodeficiency virus patients (95% confidence interval)

  Variable    Number   Overall period         2000--2009              2010--2014
  ----------- -------- ---------------------- ----------------------- ----------------------
  Total       53/322   39.24 (29.40--51.33)   42.04 (27.21--62.06)    36.97 (24.56--53.43)
  Women       1/43     4.84 (1.23--26.96)     0 (0--33.19)            8.59 (2.18--47.87)
  Men total   52/279   45.46 (33.95--59.61)   49.57 (32.08--73.18)    42.12 (27.76--61.28)
   MSM        30/139   56.63 (38.21--80.84)   63.87 (34.92--107.16)   51.35 (29.35--83.39)
   MSW        22/140   35.82 (22.45--54.24)   38.58 (19.26--69.04)    33.39 (16.67--59.75)

MSM, men who have sex with men; MSW, men who sex with women.
